FDAsafety guidance83% confidence
FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Incyte.
Regulatory Analysis
Learn more about actions to accelerate and modernize clinical research across the full continuum of drug development —from the Investigational New Drug (IND) phase to late-stage pivotal trials.
Supporting Context
- Therapeutic area
- Hematology · Chronic Myelomonocytic Leukemia
- Sub-indication
- General
Related signal: Phase 2 Study of Ruxolitinib in Chronic Myelomonocytic Leukemia Shows Potential for Improved Outcomes